Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
Abstract Background Interleukin (IL)-6 plays an essential role in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA). Tocilizumab (TCZ), a kind of biological agent against both membrane and soluble IL-6 receptor, is the only biological agent approved for the treatment of sJIA in China...
Main Authors: | Meng Xu, Congcong Liu, Lishuang Guo, Sirui Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Pediatrics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12887-020-02032-w |
Similar Items
-
Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
by: E. I. Alekseeva, et al.
Published: (2016-11-01) -
Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018-10-01) -
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
by: Athimalaipet V. Ramanan, et al.
Published: (2018-02-01) -
Tocilizumab in refractory juvenile idiopathic arthritis with associated uveitis: a case report
by: Filipe Sousa-Neves, et al.
Published: (2019-04-01) -
Case reports Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
by: Małgorzata Kwiatkowska, et al.
Published: (2015-08-01)